Next 60 MidCap Biotech Firms

The Biotechnology Next 60 firms includes the mid-cap biotech firms (between $2bn and $10bn) listed on the NASDAQ and NYSE stock exchanges

The companion theme of Next 60 MidCap Biotech is the selection of 30 Biotech LargeCap Firms

The top 100 Biotech Firms by market cap are also listed

Momentum highlights the trend of the average price computed over a week, compared to the monthly price average, and is indicative of the sector's resilience

Share performances can be ranked by selected time frame, from 2 weeks to one year (default), by selection  in the top-right menu

View the Analytics for fundamental ratio details 

The 1-year performance, compared to the large-cap 30 selection, is very strong but two-thirds of the constituents of the MidCap selection are ranked Above Average Risk or High Risk

The iShares Biotechnology ETF - - composed of an extensive list of more than 250 biotechnology and pharmaceutical equities, is the benchmark of this motif

The biotech selection of the Next 60 by market cap is not weighted - assuming one share of each component had been invested at the beginning of the selected period

Actual performance of , the tracker fund, maybe higher or lower, depending on the weighting and selection decided by the provider

Check the information available on the iShares Biotechnology ETF site or contact your advisor